Phaseline

Companies › Adcendo ApS

Adcendo ApS: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADCE-B05
Antibody-drug conjugate
–Phase 1Solid Tumors (Phase 1)Dec 2026
ADCE-T02
Tissue factor targeted antibody-drug conjugate
F3Phase 1Advanced Solid TumorMar 2027
ADCE-D01
anti-uPARAP antibody conjugated to topoisomerase I inhibitor via protease-cleavable linker
PLAURPhase 1Metastatic Soft Tissue SarcomaFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07362888ADCE-B05Phase 1Solid Tumors (Phase 1)OncologyDec 2026
NCT06597721ADCE-T02Phase 1Advanced Solid TumorOncologyMar 2027
NCT06797999ADCE-D01Phase 1Metastatic Soft Tissue SarcomaOncologyFeb 2029

Targets

PLAUR (1) F3 (1)

Companies with the same targets

Pfizer Curasight Sutro Biopharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.